Revolution Medicines (RVMD) CEO Mark Goldsmith Sells Shares

What Happened
Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines (RVMD), sold a total of 13,988 shares in open-market transactions on September 16, 2026. The sales consisted of 213 shares at a weighted average price of $195.01 (proceeds $41,537) and 13,775 shares at $199.30 (proceeds $2,745,402), for total gross proceeds of approximately $2,786,939. These were sales (not purchases).

Key Details

• Transaction dates: September 16, 2026; Form 4 filed September 18, 2026 (timely filing).
• Prices and amounts: 213 shares @ $195.01 (F2 notes multiple trades at $195.00–$195.03); 13,775 shares @ $199.30. Total shares sold = 13,988; total proceeds ≈ $2,786,939.
• Reason / footnotes: F1 states the transactions were made pursuant to a Rule 10b5-1 plan adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting. F2 discloses the trade-price range and willingness to provide per-trade prices if requested.
• Holdings notes: F3 indicates reported holdings include 157,588 restricted stock units. F4–F6 indicate portions of holdings are held in various family revocable trusts.
• Filing timeliness: Filing appears timely (reported transaction 9/16; filed 9/18).

Context

• These were pre-arranged open-market sales under a 10b5-1 plan to cover tax withholding on vested restricted stock units, a common and routine reason for insider sales. Such sales do not by themselves indicate the insider’s view of the company’s prospects.
• The filing discloses the mechanics (multiple trades and weighted-average pricing) and notes the filer will provide detailed per-trade prices on request.